OSI-906 + Paclitaxel
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Ovarian Cancer
Conditions
Ovarian Cancer, Solid Tumors
Trial Timeline
Aug 5, 2009 → Aug 25, 2014
NCT ID
NCT00889382About OSI-906 + Paclitaxel
OSI-906 + Paclitaxel is a phase 1/2 stage product being developed by Astellas Pharma for Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00889382. Target conditions include Ovarian Cancer, Solid Tumors.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00889382 | Phase 1/2 | Completed |
Competing Products
20 competing products in Ovarian Cancer